skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review

Review

(4730) Views  (997) Full article downloads

Authors: Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel Geller

Published Date March 2009 Volume 2009:5 Pages 215 - 226
DOI: http://dx.doi.org/10.2147/NDT.S3896

Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel Geller

Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USA

Objective: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD).

Methods: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD.

Results: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine’s therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported.

Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine’s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity.

Keywords: ADHD, atomoxetine, pediatric








Readers of this article also read:

Update on duloxetine for the management of stress urinary incontinence
Psychopharmacology of ADHD in pediatrics: current advances and issues
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Duloxetine for the management of fibromyalgia syndrome
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride
Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
Preferences related to attention-deficit/hyperactivity disorder and its treatment
Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan